8-KLeadership ChangesExhibits & Filings

ELI LILLY & Co 8-K Report, Executive Changes (Feb 9, 2017)

Filed February 9, 2017For Securities:LLY

Summary

Eli Lilly and Company (LLY) announced on February 7, 2017, the election of Carolyn R. Bertozzi to its Board of Directors, effective February 10, 2017. Dr. Bertozzi, a distinguished professor at Stanford University and Investigator at the Howard Hughes Medical Institute, brings a strong background in chemistry and molecular biology. Her appointment is expected to enhance the board's expertise in scientific and policy matters. Dr. Bertozzi's addition to the board signifies Lilly's commitment to leveraging deep scientific knowledge to guide its strategic direction. She will serve on the Public Policy and Compliance Committee and the Science and Technology Committee. Investors can view this as a positive development, indicating a focus on innovation and robust governance. The company has also furnished a press release detailing this appointment as an exhibit to the 8-K filing.

Key Highlights

  • 1Eli Lilly & Co. appointed Carolyn R. Bertozzi to its Board of Directors, effective February 10, 2017.
  • 2Dr. Bertozzi is a Professor at Stanford University and an Investigator at the Howard Hughes Medical Institute, bringing significant scientific expertise.
  • 3She will serve on the Public Policy and Compliance Committee and the Science and Technology Committee.
  • 4Dr. Bertozzi's appointment enhances the board's scientific and policy-related capabilities.
  • 5There are no known conflicts of interest or undisclosed arrangements related to her appointment.
  • 6She will participate in the standard director compensation program as outlined in the 2016 Proxy Statement.
  • 7A press release announcing the appointment was furnished as an exhibit.

Frequently Asked Questions

Carolyn R. Bertozzi is a renowned scientist with a Ph.D. in chemistry from UC Berkeley. She is currently a professor at Stanford University in Chemistry, Chemical and Systems Biology, and Radiology, and also an Investigator at the Howard Hughes Medical Institute. Her expertise lies in chemistry and molecular biology, with prior academic experience at UC Berkeley.

Dr. Bertozzi will serve on two key committees of the Board of Directors: the Public Policy and Compliance Committee and the Science and Technology Committee.

Dr. Bertozzi will receive compensation in accordance with the company's director compensation program, as detailed in Eli Lilly's 2016 Proxy Statement.

According to the filing, there are no arrangements between Dr. Bertozzi and any person related to her selection as a director, nor is she a party to any transactions subject to Regulation S-K involving the company or its subsidiaries.